TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05753059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
Study: NCT05753059
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Study: NCT05753059
Drug: Bendroflumethiazide
Normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Study: NCT05932446
Drug: LY3819469
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT04285320
Drug: Antibiotic oral suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)
Study: NCT06026891
Drug: MG-K10/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MG-K10 Humanized Monoclonal Antibody Injection
Study: NCT04894617
Drug: Lactose monohydrate
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate two tablet daily for a total of 5 days.
Study: NCT05305599
Drug: ZED1227
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
Study: NCT05305599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05984134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 subjects will be randomly assigned to the placebo for 7 days
Study: NCT06538623
Drug: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
Study: NCT06538623
Drug: Tegodor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
Study: NCT05435378
Drug: Vitamin B3 100 MG Oral Tablet
Normalized name: vitamin B3 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
Study: NCT05435378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
Study: NCT04767009
Drug: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
Study: NCT04590495
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Study: NCT01997268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn Oil
Study: NCT01997268
Drug: SC401B 2 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01997268
Drug: SC401B 4 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01997268
Drug: SC401B 6 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04600167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in the control group will receive placebo once weekly for 12 weeks
Study: NCT06249750
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
Study: NCT06249750
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
Study: NCT04949438
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
Study: NCT04942275
Drug: Pre-therapeutic imaging test
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
Study: NCT05181007
Drug: Mefanamic Acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
Study: NCT05157100
Drug: Ingrezza Pill
Normalized name: Ingrezza Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
Study: NCT06423235
Drug: regular dose of JiRui® Prunella oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 10ml twice a day
Study: NCT06423235
Drug: 2x regular dose of JiRui® Prunella oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 20ml twice a day
Study: NCT06423235
Drug: regular dose of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 10ml twice a day
Study: NCT06423235
Drug: 2x regular dose of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 20ml twice a day
Study: NCT05047991
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
Study: NCT05047991
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
Study: NCT05749081
Drug: Placebo in combination with vonorazan dual therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
Study: NCT05186467
Drug: intraperitoneal Magnesium sulfate
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
Study: NCT05186467
Drug: intravenous magnesium sulfate
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
Study: NCT05091528
Drug: SBT6050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
Study: NCT05091528
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 PO BID for 14 days of each 21-day cycle
Study: NCT06379490
Drug: Lidocaine epinephrine
Normalized name: epinephrine / lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine
Study: NCT05052229
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide gas for inhalation
Study: NCT03906318
Drug: Iticitinib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06272747
Drug: XH-S003
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study: NCT06272747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study: NCT04996303
Drug: Routine steroid administration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
Study: NCT05724602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
Study: NCT06663176
Drug: RESP302
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide agent
Study: NCT06663176
Drug: RESP303
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitric Oxide agent
Study: NCT06444620
Drug: DTG/3TC
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
Study: NCT05002946
Drug: SP-104
Normalized name: SPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT05567731
Drug: long GnRHa
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
Study: NCT05525819
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Study: NCT05525819
Drug: Intrathecal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Study: NCT05525819
Drug: Intravenous group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
Study: NCT05028374
Drug: A single booster dose of the Moderna mRNA COVID-19 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
Study: NCT05118841
Drug: ZX-4081
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Study: NCT05837104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, three times daily for four weeks.
Study: NCT05649605
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
Study: NCT05407961
Drug: LY3532226
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05407961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT05022810
Drug: New Paracetamol Oral Suspension (24 mg/ml)
Normalized name: New Day Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study: NCT05022810
Drug: Panadol B&I Oral Suspension (24 mg/ml paracetamol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Study: NCT06506539
Drug: Placental Extract
Normalized name: human placental tissue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: add placental extract gel as a local delivery drug in periodontal pocket
Study: NCT06508359
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
Study: NCT06176508
Drug: HS-10374-matched placebo tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally QD for 16 weeks
Study: NCT05198791
Drug: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Study: NCT01420666
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 325 mg, three tablets four times a day, orally, with food
Study: NCT01420666
Drug: Maxigesic 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
Study: NCT01420666
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 97.5mg, three tablets four times a day, orally, with food
Study: NCT01420666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, three tablets four times a day, orally, with food
Study: NCT05986903
Drug: Tumor necrosis factor (TNF)-alpha inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive drug monitoring was defined as the assessment of trough concentrations to optimize dosing during induction therapy and intermittently thereafter regardless of symptoms or inflammatory markers.~During induction, the following target concentrations are employed: 25-30 mcg/ml (week 2) and 20 mcg/ml (week 6) for Infliximab and \> 10 mcg/ml (week 2 and 4) for Adalimumab. Checks are performed systematically at week 2 and 6 (infliximab) and at week 4 (adalimumab).~During the maintenance, the targets are 5-10 mcg/ml for Infliximab and 8-12 mcg/ml for Adalimumab. In case of perianal disease, the targets are 7-20 mcg/ml.
Study: NCT04708327
Drug: STAT-205
Normalized name: zinc oxide 0.205 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone hydrochloride capsules 4.5 mg each
Study: NCT05475184
Drug: JPI-547
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.
Study: NCT05052619
Drug: Preventive use of advanced antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
Study: NCT06267638
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intraoperative normal saline during total knee arthroplasty
Study: NCT04874506
Drug: MBM-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Study: NCT05402995
Drug: Irrisept (Irrigation Solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
Study: NCT04890392
Drug: PD-1 inhibitor(Tislelizumab) ,SOX(S-1+ Oxaliplatin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1: 40\~60mg Bid，d1\~14, q3w. Oxaliplatin：130mg/m2，iv drip for 2h，d1, q3w. PD-1（Tislelizumab）:200mg,iv drip for at least 1h,d1,q3w. Stage I: PD1 inhibitor + SOX regimen (q3W) . Stage II: PD1 inhibitor + SOX regimen (q3W) Stage III: PD1 inhibitor + SOX regimen (q3W) . Efficacy evaluation,then followed by surgery.
Study: NCT05543785
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After confirmation of circulatory isolation of the operated limb by the inflated tourniquet, 30 mg ketorolac tromethamine diluted in normal saline in a total volume of 50 ml will be injected
Study: NCT05545670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: not containing drugs
Study: NCT06184438
Drug: Micronized purified flavonoid fraction(Daflon 1000mg)
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received Micronized purified flavonoid fraction(Daflon 1000mg) BID after surgery from day to day 7
Study: NCT06184438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received placebo after surgery.
Study: NCT05951712
Drug: N Acetyl cysteine 600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Study: NCT05951712
Drug: Simethicone 150mg plus N Acetyl cysteine 600 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Impact of simethicone plus N Acetyl cysteine on the mucosal visibility of stomach and duodenum
Study: NCT05114603
Drug: HLX208
Approvals — FDA: no, EMA: no, PMDA: no
Description: level 1:600mg po Bid level 2:900mg po Bid
Study: NCT04989049
Drug: Folic Acid 5 MG
Normalized name: folic acid 5 MG
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: folic acid tablet of 5mg will be placed on the ulcers 2 times per day for 7 days
Study: NCT00002275
Drug: Fat Emulsion 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002275
Drug: Fat Emulsion 20%
Normalized name: Fat Emulsion 20% Intravenous Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06414499
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical care according to the guideline (Stroke. 2019;50(12): e344-e418.). Antiplatelet therapy is chosen by researchers-Single/dual antiplatelet therapy can be chosen.
Study: NCT00000984
Drug: CD4 Antigens
Normalized name: TRICOPHYTON ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05378074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Study: NCT06164873
Drug: IBI362
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly injections of gradually increased doses of IBI362
Study: NCT06164873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly injections of volume-matched placebo
Study: NCT05097794
Drug: BR1015-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.